Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Coronavirus COVID-19 Vaccines Infectious Diseases

UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts

MHRA Rejects Low Dose Data

  • News

Executive Summary

UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.

You may also be interested in...



AstraZeneca Applies For EU Approval Of COVID-19 Vaccine

The European Medicines Agency may issue an opinion on approving AstraZeneca’s COVID-19 vaccine by 29 January if the data are robust and complete and any additional data requests are dealt with promptly.

EU Approval Of Oxford/AstraZeneca COVID-19 Vaccine Expected By End Of January

AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week. The vaccine was developed in partnership with the University of Oxford. 

Operation Warp Speed’s Difficult Holiday Season

The US missed even its revised year-end target for COVID vaccines, but the news isn’t all bad; there’s steady progress on clinical research even as federal officials seem out of ideas for how to speed actual vaccinations.

Table

View full table

Related Content

Pink Sheet
Scrip
Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 Vaccines Infectious Diseases
UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By